In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Compound and Digenic Heterozygosity Predicts Life-Time Arrhythmic Outcome and Sudden Cardiac Death in Desmosomal Gene-Related Arrhythmogenic Right Ventricular Cardiomyopathy.

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined disorder, caused by mutations in the genes encoding for the desmosomal proteins in more than 50% of the index cases. Disease manifests with potentially life-threatening ventricular arrhythmias. Until recently, the role of genetic testing was restricted mainly to disease diagnosis; however, novel studies have associated more complex genetic status with disease penetrance and clinical expression. This is the first study to systematically evaluate genetic predictors of lifetime arrhythmic outcome and sudden cardiac death.
Myocardial Disease


Methods and Results:

The study population consisted of 134 carriers of mutations in genes encoding desmosomal proteins (44 probands, 90 family members). Endpoint outcome was defined as sudden cardiac death (SCD), aborted SCD, sustained ventricular tachycardia and appropriated ICD intervention.113 (84%) individuals had a single mutation which in DSP (n=44), PKP-2 (n=38), DSG-2 (n=30) and DSC-2 (n=1); in 62 of them its was a missense mutation and in the rest 51 a non-missense mutation. 21 (16%) individuals had complex mutations; compound heterozygocity was present in 7 and digenic heterozygocity in 14. Disease penetrance, defined as either a definite or borderline diagnosis based on the 2010 revised task force criteria, occurred in 78 (58%) mutation carriers. Carriers of multiple mutations had higher rates of disease penetrance (p=0.03). Among these patients low voltage and left ventricular (LV) dysfunction was more frequent within males (p values 0.04 and 0.001 respectively). Multiple mutation carriers exhibited an increased incidence of epsilon waves (p=0.001), right precordial T-wave inversion (TWI) beyond V3 (p=0.02), late potentials (p=0.04), lower right ventricular functional (RV) area change (p=0.001) and multiple right ventricular wall motion abnormalities (p=0.01). Within the group of single mutation carriers, increased incidence of right precordial TWI beyond lead V3 (p=0.006) and lower RV fractional area change (p=0.06) was found in non-missense as compared to missense mutation carriers. Individuals with a single mutation in the DSP gene had more frequent TWI in leads V4 to V6 (p=0.02), low QRS voltage in limb leads (p=0.02) and LV dysfunction (p=0.01) as compared to single mutation carriers of the rest desmosomal genes. 22 (16%) of the mutation carriers reached the endpoint outcome (12/44 probands and 10/90 family members). Multivariate analysis revealed the presence of multiple mutations and male gender to be independent predictors of the endpoint outcome (HR 3.71 and 2.76 respectively). Lifetime endpoint rate was incremental between the groups of females with single mutation (7%), males with single mutation (13%), females with multiple mutations (27%) and males with multiple mutations (63%).



Discussion:

The main result of this study is that the presence of a complex genotype was found in 16% of the cohort and independently predicted the occurrence of major arrhythmic events. Although, this hypothesis has been suggested before, this is the first study capable to support it. Additionally this group of patients experienced an increased disease penetrance with more prevalent depolarization and repolarization changes on ECG and structural/functional alterations on two-dimensional echocardiography. These findings suggest that multiple mutations probably have an additive effect on disease pathophysiology and that comprehensive screening of all desmosomal genes might be beneficial for patients in terms of risk assessment. 

Conclusion:

However it is, yet, unclear how this information can be implemented into a more comprehensive clinical risk stratification model for patients with ARVC. Under these circumstances, in the era of next generation sequencing, observed genetic variances need to be interpreted with great care in order not to mislead patient diagnosis and management.

References


Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129-133.

Basso C, Corrado D, Bauce B, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2012;5:1233-1246.

 Basso C, Corrado D, Marcus F, Nava A, Thiene G. Arrhythmogenic right ventricular
cardiomyopathy. Lancet. 2009;373:1289-1300.

Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006;113:1634-1637.

Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic
cardiomyopathy. Nat Rev Cardiol. 2012;9:223-233.

Van Hengel J, Calore M, Bauce B, Dazzo E, Mazzotti E, De Bortoli M, et al. Mutations In the area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34:201-210.

Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical
management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart. 2011;97:530-539.

Cox MG, van der Zwaag PA, van der Werf C, van der Smagt JJ, Noorman M, Bhuiyan ZA, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: pathogenic desmosome mutations in index-patients predict outcome of family screening: Dutch arrhythmogenic right ventricular dysplasia/cardiomyopathy genotype-phenotype follow-up study. Circulation. 2011;123:2690-2700.

Kapplinger JD, Landstrom AP, Salisbury BA, Callis TE, Pollevick GD, Tester DJ, et al.Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. J Am Coll Cardiol. 2011;57:2317-2327

Migliore F, Zorzi A, Silvano M, Bevilacqua M, Leoni L, Marra MP, et al. Prognostic value of endocardial voltage mapping in patients with Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circ Arrhythm Electrophysiol. 2013;6:167-176

Rizzo S, Lodder EM, Verkerk AO, Wolswinkel R, Beekman L, Pilichou K, et al. Intercalated disc abnormalities, reduced Na(+) current density, and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes.
Cardiovasc Res. 2012;95:409-418

Bauce B, Rampazzo A, Basso C, Mazzotti E, Rigato I, Steriotis A, et al. Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations. Heart Rhythm. 2011;8:1686-1695.

 

Notes to editor


Presented by : Alexandros Protonotarios, MD. Yannis Protonotarios Medical Centre, Naxos, Greece, Aris Anastastakis, MD, PhD. 1st Department of Cardiology, University of Athens Medical School, Athens, Greece

Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, Migliore F, Perazzolo Marra M, Lorenzon A, De Bortoli M, Calore M, Nava A, Daliento L, Gregori D, Iliceto S, Thiene G, Basso C, Corrado D. Circ Cardiovasc Genet. 26 Sept 2013
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.